|
|
|
Volumn 26, Issue 4 SUPPL. 12, 1999, Pages 84-88
|
|
Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)
a
a
QOL Consulting
(Canada)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ANALYTIC METHOD;
ARTICLE;
BREAST CANCER;
BREAST METASTASIS;
CLINICAL TRIAL;
DRUG EFFICACY;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
ONCOGENE NEU;
OUTCOMES RESEARCH;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RISK BENEFIT ANALYSIS;
SCORING SYSTEM;
SOCIAL INTERACTION;
WELLBEING;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
FEMALE;
HUMANS;
NEOPLASM METASTASIS;
RECEPTOR, ERBB-2;
SICKNESS IMPACT PROFILE;
|
|
EID: 0032825105
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (48)
|
|
References (7)
|
